Infographic: The Big Pharma Takeover of Medical Cannabis
Connect with us

Markets

The Big Pharma Takeover of Medical Cannabis

Published

on

INFO

The Big Pharma Takeover of Medical Cannabis

As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.

Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.

Who are “Big Pharma”?

The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.

So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.

Could Cannabis be Sold Over the Counter?

The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.

Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:

  • Epilepsy
  • Schizophrenia
  • Multiple sclerosis
  • Migraines
  • Arthritis
  • Cancer side effects

As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.

As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.

Big Pharma’s Foray into Cannabis

Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.

Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.

Company Rank🇨🇦 Canadian PatentsCompany Rank🇺🇸 U.S. Patents
1. Novartis211. Abbvie59
2. Pfizer142. Sanofie39
3. GW Pharmaceuticals133. Merck35
4. Ericsson134. Bristol-Myers Squibb34
5. Merck115. GW Pharmaceuticals28
6. Solvay Pharmaceuticals76. Pfizer25
7. Kao Corporation77. Hebrew University of Jerusalem19
8. Ogeda SA78. Roche17
9. Sanofi69. University of Connecticut16
10. University of Connecticut610. U.S. Health and Human Services13

It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.

Data is the Missing Link

While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.

Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.

Subscribe to Visual Capitalist
Click for Comments

Markets

When Will Air Travel Return to Pre-Pandemic Levels?

COVID-19 hit the air travel industry hard. But passenger traffic is slowly recovering, and by 2025, things are expected to return to ‘normal.’

Published

on

when will air travel return to pre-COVID levels?

When Will Air Travel Return to Pre-Pandemic Levels?

Many industries were hit hard by the global pandemic, but it can be argued that air travel suffered one of the most severe blows.

The aviation industry as a whole suffered an estimated $370 billion loss in global revenue because of COVID-19. And while air travel has been slowly recovering from the trough, flight passenger traffic has yet to fully bounce back.

Where is the industry at in 2022 compared to pre-COVID times, and when is air passenger travel expected to return to regular levels? This graphic by Julie R. Peasley uses data from IATA to show current and projected air passenger ridership.

Air Travel Traffic: 2021 and 2022

After an incredibly difficult 2020, the airline industry started to see significant improvements in travel frequency. But compared to pre-pandemic levels, there’s a lot of ground to cover.

In 2021, overall passenger numbers only reached 47% of 2019 levels. This influx was largely driven by domestic travel, with international passenger numbers only reaching 27% of pre-COVID levels.

Passenger numbers (% of 2019)20212022
International27%69%
Domestic61%93%
Africa46%76%
Asia Pacific40%68%
Caribbean44%72%
Central America72%96%
Europe40%86%
Middle East42%81%
North America56%94%
South America51%88%
Industry-wide47%83%

From a regional perspective, Central America experienced one of the fastest recoveries. In 2021, overall passenger numbers in the region had reached 72% of 2019 levels, and they are projected to reach 96% by the end of 2022.

In fact, the Americas as a whole has seen a quick recovery. Both North America and South America also reached above 50% of 2019 ridership in 2021, and are projected to reach 94% and 88% ridership in 2022, respectively.

On the opposite end of the spectrum, Asia Pacific has experienced the slowest recovery. This is likely due to stricter lockdowns and travel restrictions put into effect in this region (which was harder hit by SARS in 2003), especially in places like Shanghai.

Forecasting Traffic in 2023 and Beyond

While recovery has looked different from region to region, airlines are largely expected to see a full recovery to their ridership levels by 2025.

Forecasted Passengers (% of 2019)202320242025
International82%92%101%
Domestic103%111%118%
Africa85%93%101%
Asia Pacific84%97%109%
Caribbean82%92%101%
Central America102%109%115%
Europe96%105%111%
Middle East90%98%105%
North America102%107%112%
South America97%103%108%
Industry-wide94%103%111%

This recovery is a signifier of a much broader mindset shift, as governments continue to reassess their COVID-19 management strategies.

But while the future seems promising, IATA stressed that the forecast does not take into account the potential impact of the Russia-Ukraine conflict and other geopolitical concerns, which could have far-reaching consequences on the global economy (and travel) in the coming years.

Continue Reading

Markets

All of the World’s Money and Markets in One Visualization (2022)

From the wealth held to billionaires to all debt in the global financial system, we look at the vast universe of money and markets in 2022.

Published

on

All of the World’s Money and Markets in One Visualization

The era of easy money is now officially over.

For 15 years, policymakers have tried to stimulate the global economy through money creation, zero interest-rate policies, and more recently, aggressive COVID fiscal stimulus.

With capital at near-zero costs over this stretch, investors started to place more value on cash flows in the distant future. Assets inflated and balance sheets expanded, and money inevitably chased more speculative assets like NFTs, crypto, or unproven venture-backed startups.

But the free money party has since ended, after persistent inflation prompted the sudden reversal of many of these policies. And as Warren Buffett says, it’s only when the tide goes out do you get to see “who’s been swimming naked.”

Measuring Money and Markets in 2022

Every time we publish this visualization, our common unit of measurement is a two-dimensional box with a value of $100 billion.

Even though you need many of these to convey the assets on the balance sheet of the U.S. Federal Reserve, or the private wealth held by the world’s billionaires, it’s quite amazing to think what actually fits within this tiny building block of measurement:

What fits in a $100 billion box?

Our little unit of measurement is enough to pay for the construction of the Nord Stream 2 pipeline, while also buying every team in the NHL and digging FTX out of its financial hole several times over.

Here’s an overview of all the items we have listed in this year’s visualization:

Asset categoryValueSourceNotes
SBF (Peak Net Worth)$26 billionBloombergNow sits at <$1B
Pro Sports Teams$340 billionForbesMajor pro teams in North America
Cryptocurrency$760 billionCoinMarketCapPeaked at $2.8T in 2021
Ukraine GDP$130 billionWorld BankComparable to GDP of Mississippi
Russia GDP$1.8 trillionWorld BankThe world's 11th largest economy
Annual Military Spending$2.1 trillionSIPRI2021 data
Physical currency$8.0 trillionBIS2020 data
Gold$11.5 trillionWorld Gold CouncilThere are 205,238 tonnes of gold in existence
Billionaires$12.7 trillionForbesSum of fortunes of all 2,668 billionaires
Central Bank Assets$28.0 trillionTrading EconomicsFed, BoJ, Bank of China, and Eurozone only
S&P 500$36.0 trillionSlickchartsNov 20, 2022
China GDP$17.7 trillionWorld Bank
U.S. GDP$23.0 trillionWorld Bank
Narrow Money Supply$49.0 trillionTrading EconomicsIncludes US, China, Euro Area, Japan only
Broad Money Supply $82.7 trillionTrading EconomicsIncludes US, China, Euro Area, Japan only
Global Equities$95.9 trillionWFELatest available 2022 data
Global Debt$300.1 trillionIIFQ2 2022
Global Real Estate$326.5 trillionSavills2020 data
Global Private Wealth$463.6 trillionCredit Suisse2022 report
Derivatives (Market)$12.4 trillionBIS
Derivatives (Notional)$600 trillionBIS

Has the Dust Settled Yet?

Through previous editions of our All the World’s Money and Markets visualization, we’ve created snapshots of the world’s assets and markets at different points in time.

For example, in our 2017 edition of this visualization, Apple’s market capitalization was only $807 billion, and all crypto assets combined for $173 billion. The global debt total was at $215 trillion.

Asset2017 edition2022 editionChange (%)
Apple market cap$807 billion$2.3 trillion+185%
Crypto$173 billion$760 billion+339%
Fed Balance Sheet$4.5 trillion$8.7 trillion+93%
Stock Markets$73 trillion$95.9 trillion+31%
Global Debt$215 trillion$300 trillion+40%

And in just five years, Apple nearly quadrupled in size (it peaked at $3 trillion in January 2022), and crypto also expanded into a multi-trillion dollar market until it was brought back to Earth through the 2022 crash and subsequent FTX implosion.

Meanwhile, global debt continues to accumulate—growing by $85 trillion in the five-year period.

With interest rates expected to continue to rise, companies making cost cuts, and policymakers reining in spending and borrowing, today is another unique snapshot in time.

Now that the easy money era is over, where do things go from here?

Continue Reading

Subscribe

Popular